Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

incobotulinumtoxinA

Known as: BoNT-A 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Objective This pivotal phase III study, SIAXI, investigated the efficacy and safety of incobotulinumtoxinA for the treatment of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
2017
2017
Objective: To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2016
2016
Introduction: Efficacy and safety of incobotulinumtoxinA in post‐stroke upper‐limb spasticity were studied. Methods: Subjects… Expand
2014
2014
Typically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approximately 3-month… Expand
  • table 1
  • figure 1
  • table 2
2013
2013
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… Expand
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 3
2013
2013
IncobotulinumtoxinA (Xeomin®, NT 201), a preparation without accessory (complexing) proteins, has shown comparable efficacy and… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Highly Cited
2011
Highly Cited
2011
OBJECTIVE IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
2011
Highly Cited
2011
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… Expand
  • table 1
  • table 2
2011
2011
  • M. Imhof, U. Kühne
  • The Journal of clinical and aesthetic dermatology
  • 2011
  • Corpus ID: 43319090
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… Expand
Highly Cited
2010
Highly Cited
2010
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4